Treating major depression has usually meant choosing between daily pills with tricky side effects or making tedious daily trips to a clinic for advanced medical procedures. Swedish neurotech company Flow Neuroscience is officially shaking up that dynamic by launching its FL-100 headset across the United States, bringing FDA-cleared brain stimulation right into patients’ living rooms.
This is not some random biohacking gadget you buy off an internet ad. Following its milestone FDA Premarket Approval under PMA P230024, this prescription-only device offers adults dealing with moderate to severe depression a genuine non-drug alternative. Doctors can prescribe it as a monotherapy or adjunct to available antidepressant drugs if the patient is not treatment-refractory.
How low-level stimulation targets mood regulation
The technology that powers the FL-100 wireless headset is based on transcranial direct current stimulation, or tDCS. It connects to a smart phone app and provides a light low intensity electrical current of 0.5 to 2.0 mA directly to the left dorsolateral prefrontal cortex. This is the particular part of the brain that regulates mood and cognitive control.
The actual treatment routine is pretty straightforward but structured. Patients complete 15 half-hour sessions across the first three weeks, followed by three maintenance sessions per week after that. The companion app controls stimulation timing to prevent overuse and tracks symptom progress using validated scales to keep it safe and controlled. It also automatically syncs adherence data back to the prescribing clinician for remote review.
Clinical evidence and US availability
The medical backing here is solid, drawing from the 10-week, double-blind EMPOWER trial published in Nature Medicine. In the study, 57% of patients receiving active stimulation hit full clinical remission. Plus, around 63% saw their symptoms cut at least in half. The reported side effects were mostly minor and temporary, consisting mainly of slight skin redness and mild tingling where the electrodes touch the forehead.
Flow Neuroscience already brings plenty of real-world experience to its American rollout. The company’s technology has treated over 65,000 users across Europe, the UK, and Australia with the help of more than 1,200 prescribing health professionals.
To roll out the device in the US, the company is opening prescribing pathways for psychiatrists, primary care doctors, and nurse practitioners. It’s also offering remote patient evaluations through its Flow Care telehealth network.
Insurance coverage is still evolving and out-of-pocket costs are expected to be between $500 and $800. Still, launching the FL-100 sets a permanent regulatory precedent for home-delivered neurostimulation in the US market.
The post Flow Neuroscience Launches FL-100: An At-Home Option for Depression Treatment with Brain Stimulation appeared first on Android Headlines.
​Â
